newsfilter
← Latest News
GlobeNewswire·

Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027 QTORIN™ Rapamycin Could Become the First FDA-Approved Therapy